Evaluation of Progesterone Utilization and Birth Outcomes in a State Medicaid Plan

Monday, October 30, 2017
Cover image
Tasmina Hydery, PharmD, MBA, CGP
University of Massachusetts Medical School
Mylissa Price, MPH, BS, RPh
University of Massachusetts Medical School
Bonnie Greenwood, PharmD, BCPS
University of Massachusetts Medical School
Mito Takeshita, PharmD
University of Massachusetts Medical School
Parag Kunte, MPH
University of Massachusetts Medical School
Kimberly Lenz, PharmD
University of Massachusetts Medical School
Rose Mauro, MPH, CPh
University of Massachusetts Medical School
Paul L. Jeffrey, PharmD
University of Massachusetts Medical School

Researchers found that members of the Massachusetts Medicaid program, MassHealth, had low levels of medication adherence when prescribed progesterone to prevent pre-term birth. This finding is in line with previous studies that revealed progesterone adherence rates are typically low. The study suggests there may be barriers to adherence for pregnant women who are prescribed progesterone, and  concludes that support may increase adherence rates.

This study tracked the effects of progesterone in reducing premature births, reported birth outcomes, and Medicaid adherence among MassHealth members receiving progesterone. It references data from between 2011-2015 in the form of medical and pharmacy claims, and prior authorization (PA) request data for MassHealth members that used progesterone. This study was presented at the American Drug Utilization Review Society Conference in Scottsdale, Arizona, Feb. 24, 2017. 

Conference 
American Drug Utilization Review Society Conference